FDA Litigates To Wash Off Sanitizer Ebola Claim, Warns On Colloidal Silver Benefits
This article was originally published in The Rose Sheet
A complaint filed in federal court in California seeks an order to block Innovative BioDefense from distributing Zylast antiseptic hand sanitizer products that, due to its claims, are unapproved new drugs under FDA regulations. A warning letter to Silver Armor states that drug claims render its Silver Ramon and Natural Health brand products, which contain colloidal silver, unapproved new drugs and that the is noncompliant with supplement GMP regulations.
You may also be interested in...
Claims that Germstar antiseptic cleanser line treat swine flu, E-coli, salmonella and norovirus are not part of an OTC final monograph or TFM, FDA says in warning letter. The products contain active ingredients FDA deferred from OTC monographs for consumer and health care rubs to await additional data.
FDA doesn't expect o continue increasing GMP inspections at the rate established from fiscal 2013 through 2017, says Cara Welch, assistant director of the office in the agency's Office of Dietary Supplement Programs."We're not going to keep growing at that rate because we have a lot of regulations we have to inspect and we're always resource strapped," she said at a recent industry conference.
FTC joins FDA in one of the three warning letters to firms claiming their products can either prevent or treat Ebola.